Status:
COMPLETED
T-cell Subsets in Rheumatoid Arthritis Patients on Long-term Anti-TNF or IL6-receptor-blocker Therapy
Lead Sponsor:
Szeged University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Data on the impact of biological therapies, especially of IL6-blocker treatment, on the T-cell phenotype in rheumatoid arthritis (RA) are limited, inconclusive, and mainly involve short-term follow-up...
Eligibility Criteria
Inclusion
- Inclusion Criteria for patients:
- Diagnosis of rheumatoid arthritis classified according to the 2010 ACR/EULAR classification criteria for RA
- Biological treatment with anti-TNF therapy (adalimumab or certolizumab pegol or etanercept or infliximab or golimumab) or anti-IL-6R agent (tocilizumab)
- Inclusion Criteria for healthy controls:
- negative history of RA symptoms
- negative status upon detailed physical and laboratory examination including normal CRP and ESR values
- Exclusion Criteria:
- other autoimmune comorbidity
- lack of informed consent
Exclusion
Key Trial Info
Start Date :
January 2 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2016
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT03266822
Start Date
January 2 2013
End Date
May 31 2016
Last Update
August 30 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.